With the World Health Organisation declaring the coronavirus outbreak a pandemic, attention has turned to the prospect of a vaccine. Around 35 companies and academic institutions around the world are racing to develop tests, treatments and vaccines to combat the Covid-19 virus.
Moderna Therapeutics, a Boston-based biotech company, shipped its first batch of Covid-19 vaccine to the National Institute of Allergy and Infectious Diseases (NIAID) just 42 days after the genetic sequence of coronavirus and the first participant has been dosed in the Phase 1 study.
Researchers at the Academy of Military Medical Sciences (AMMS) in China and CanSino, a Hong Kong-listed biotech firm, have also reportedly received approval this week to launch early-stage clinical trials of a potential vaccine. The Chinese trial registration database intends to recruit 108 healthy participants between 16th March and 31st December to complete a Phase 1 test evaluating the safety of the experimental shot in humans.